Therapeutic and Supportive Effects of Cannabinoids in Patients with Brain Tumors (CBD Oil and Cannabis).
Antitumor therapy
Cannabinoids
Gliomas
Palliative care
Symptom management
Journal
Current treatment options in oncology
ISSN: 1534-6277
Titre abrégé: Curr Treat Options Oncol
Pays: United States
ID NLM: 100900946
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
pubmed:
13
1
2023
medline:
25
1
2023
entrez:
12
1
2023
Statut:
ppublish
Résumé
The potential medicinal properties of Cannabis continue to garner attention, especially in the brain tumor domain. This attention is centered on quality of life and symptom management; however, it is amplified by a significant lack of therapeutic choices for this specific patient population. While the literature on this matter is young, published and anecdotal evidence imply that cannabis could be useful in treating chemotherapy-induced nausea and vomiting, stimulating appetite, reducing pain, and managing seizures. It may also decrease inflammation and cancer cell proliferation and survival, resulting in a benefit in overall patient survival. Current literature poses the challenge that it does not provide standardized guidance on dosing for the above potential indications and cannabis use is dominated by recreational purposes. Furthermore, integrated and longitudinal studies are needed but these are a challenge due to arcane laws surrounding the legality of such substances. The increasing need for evidence-based arguments about potential harms and benefits of cannabis, not only in cancer patients but for other medical use and recreational purposes, is desperately needed.
Identifiants
pubmed: 36633803
doi: 10.1007/s11864-022-01047-y
pii: 10.1007/s11864-022-01047-y
pmc: PMC9867687
doi:
Substances chimiques
Cannabinoids
0
Cannabidiol
19GBJ60SN5
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
30-44Informations de copyright
© 2023. The Author(s).
Références
Biochem Biophys Res Commun. 2013 Jun 21;436(1):104-9
pubmed: 23726916
J Neurooncol. 2018 Dec;140(3):485-496
pubmed: 30377935
J Comp Neurol. 2016 Dec 15;524(18):3865-3895
pubmed: 27187682
Addiction. 2018 May;113(5):958-966
pubmed: 29271031
Lancet Neurol. 2019 Apr;18(4):376-393
pubmed: 30797715
Behav Pharmacol. 2019 Dec;30(8):676-688
pubmed: 31703030
Front Pharmacol. 2018 Nov 13;9:1259
pubmed: 30542280
FEBS Lett. 1998 Sep 25;436(1):6-10
pubmed: 9771884
Oncologist. 2014 Jul;19(7):751-9
pubmed: 24899645
Trends Neurosci. 2018 Aug;41(8):493-496
pubmed: 29907436
Ann Oncol. 2011 Sep;22(9):2086-2093
pubmed: 21343383
Nat Med. 2008 Sep;14(9):923-30
pubmed: 18776886
Handb Exp Pharmacol. 2005;(168):117-45
pubmed: 16596773
AAPS J. 2021 Jun 28;23(4):91
pubmed: 34181150
J Neurochem. 2010 Sep 1;114(5):1277-90
pubmed: 20534007
Childs Nerv Syst. 2016 Nov;32(11):2061-2067
pubmed: 27613640
Cancer Res. 2004 Mar 15;64(6):1943-50
pubmed: 15026328
Front Pharmacol. 2017 Feb 17;8:69
pubmed: 28261100
EMBO Mol Med. 2020 Jun 8;12(6):e12075
pubmed: 32346964
Front Mol Neurosci. 2017 May 31;10:174
pubmed: 28620280
J Pain Symptom Manage. 2014 Jan;47(1):166-73
pubmed: 23742737
Neurooncol Pract. 2020 Jul;7(4):376-383
pubmed: 32765889
Adv Exp Med Biol. 2021;1297:1-9
pubmed: 33537933
J Pharmacol Exp Ther. 2008 Nov;327(2):584-91
pubmed: 18664590
Neuro Oncol. 2018 Apr 9;20(5):674-686
pubmed: 29106665
BMJ. 2001 Jul 7;323(7303):16-21
pubmed: 11440936
Neuropsychiatr Dis Treat. 2020 Feb 07;16:381-396
pubmed: 32103958
J Biol Chem. 2007 Mar 2;282(9):6854-62
pubmed: 17202146
Pharmacol Rev. 2006 Sep;58(3):389-462
pubmed: 16968947
Br J Cancer. 2021 Apr;124(8):1379-1387
pubmed: 33623076
CA Cancer J Clin. 2017 Mar;67(2):91-92
pubmed: 28095590
Cancer Res. 2004 Aug 15;64(16):5617-23
pubmed: 15313899
J Pain Symptom Manage. 2013 Aug;46(2):207-18
pubmed: 23141881
Front Oncol. 2021 May 21;11:649555
pubmed: 34094937
Eur J Drug Metab Pharmacokinet. 2018 Feb;43(1):1-12
pubmed: 28534260
Acta Oncol. 2008;47(6):1062-70
pubmed: 17934890
J Clin Invest. 2002 Mar;109(6):777-85
pubmed: 11901186
J Palliat Med. 2019 Oct;22(10):1202-1207
pubmed: 31081711
J Neurol Neurosurg Psychiatry. 2004 Aug;75(8):1205-6
pubmed: 15258238
CA Cancer J Clin. 2021 Sep;71(5):381-406
pubmed: 34427324
Nature. 2001 Oct 4;413(6855):527-31
pubmed: 11586361
J Neurophysiol. 2004 Dec;92(6):3562-74
pubmed: 15317842
Brain. 2011 Apr;134(Pt 4):1041-60
pubmed: 21459826
Front Mol Neurosci. 2018 May 16;11:159
pubmed: 29867351
Nat Med. 2000 Mar;6(3):313-9
pubmed: 10700234
Integr Cancer Ther. 2021 Jan-Dec;20:15347354211061739
pubmed: 34841942
Curr Neurol Neurosci Rep. 2012 Jun;12(3):267-75
pubmed: 22453825
Neuro Oncol. 2019 Nov 1;21(Suppl 5):v1-v100
pubmed: 31675094
Br J Cancer. 2006 Jul 17;95(2):197-203
pubmed: 16804518
Cell Mol Life Sci. 2016 Dec;73(23):4449-4470
pubmed: 27402121
Nat Rev Cancer. 2012 May 04;12(6):436-44
pubmed: 22555283
Curr Oncol. 2016 Mar;23(2):S8-S14
pubmed: 27022315
Exp Neurol. 2015 Jul;269:133-41
pubmed: 25895887
Nat Rev Cancer. 2003 Oct;3(10):745-55
pubmed: 14570037
Brain Res. 2007 Mar 16;1137(1):161-9
pubmed: 17239827
Neurooncol Pract. 2022 Feb 22;9(3):165-182
pubmed: 35601966
Pharmacol Rev. 2002 Jun;54(2):161-202
pubmed: 12037135
JAMA. 2015 Jun 23-30;313(24):2456-73
pubmed: 26103030
Trends Pharmacol Sci. 2001 Jan;22(1):19-22
pubmed: 11165667
Molecules. 2014 Nov 17;19(11):18781-816
pubmed: 25407719
Front Immunol. 2017 Nov 10;8:1487
pubmed: 29176975
J Neurosci. 2012 May 16;32(20):7091-101
pubmed: 22593077
Adv Pharmacol. 2017;80:169-206
pubmed: 28826534
Neuro Oncol. 2012 Feb;14(2):230-41
pubmed: 22187341
Br J Pharmacol. 2007 Nov;152(5):765-77
pubmed: 17572696
Transl Psychiatry. 2018 Jan 31;8(1):32
pubmed: 29382825
Eur J Cancer Care (Engl). 2008 Sep;17(5):431-43
pubmed: 18625004
J Cachexia Sarcopenia Muscle. 2018 Apr;9(2):220-234
pubmed: 29400010
Springerplus. 2015 Jun 12;4(Suppl 1):L11
pubmed: 27386174
Cancers (Basel). 2021 Apr 05;13(7):
pubmed: 33916466
Curr Neuropharmacol. 2006 Jul;4(3):239-57
pubmed: 18615144